Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04649775 · ClinicalTrials.gov registry record · NA
AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19
A NA study, sponsored by Duke University.
- Terminated
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT04649775 is a NA study that was terminated before completion, run by Duke University. The registered enrollment target is 11 participants.
The verdict
NCT04649775, a NA study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
The study is an unblinded, randomized, controlled trial for use of the AirFlO2 device for patients admitted to Duke Hospital with COVID-19 and tachypnea (RR \>20 breaths/min) and/or hypoxia (Oxygen saturation \<94% on room air or requiring supplemental oxygen at baseline).
Interventions
- DEVICE AirFLO2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-04-09 |
| Est. Completion | 2021-11-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04649775
The ClinicalTrials.gov registry entry for NCT04649775 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AirFLO2 is the first listed.
NCT04649775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04649775 about?
NCT04649775 is a clinical study titled "AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19". The study is an unblinded, randomized, controlled trial for use of the AirFlO2 device for patients admitted to Duke Hospital with COVID-19 and tachypnea (RR \>20 breaths/min) and/or hypoxia (Oxygen saturation \<94% on room air or requiring supplemental oxygen at baseline).
What is the current status of trial NCT04649775?
This trial is currently terminated. It is a NA study. The enrollment target is 11 participants. The study started on 2021-04-09. Estimated completion is 2021-11-08.
What interventions are being tested in trial NCT04649775?
The interventions under investigation include: AirFLO2 (DEVICE).
Who is sponsoring clinical trial NCT04649775?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.